第三代新型抗癫痫药物布瓦西坦的研究进展  

Research progress in the third generation new antiepileptic drug brivaracetam

作　　者：李莹[1] 王鸣璐 王成彬 赵明明[1] 肇丽梅[1] LI Ying;WANG Ming-lu;WANG Cheng-bin;ZHAO Ming-ming;ZHAO Li-mei(Department of Pharmacy,Shengjing Hospital of China Medical University,Shenyang 110004)

机构地区：[1]中国医科大学附属盛京医院药学部,沈阳110004

出　　处：《中南药学》2023年第4期1008-1012,共5页Central South Pharmacy

基　　金：盛京自由研究者基金项目(No.M0779)。

摘　　要：布瓦西坦是第三代新型抗癫痫药物,是第一个高亲和力的突触囊泡蛋白2A(SV2A)配体,具有吸收速度快、生物利用度高、药物相互作用少等优点,被批准用于4岁及以上伴或不伴继发全面性发作的局灶性癫痫患者的单药治疗或辅助治疗。本文就布瓦西坦的抗癫痫作用机制、药动学特征、临床疗效、安全性及妊娠期应用等方面进行综述,以期为癫痫治疗提供更有效的药物选择。Brivaracetam is a third generation new antiepileptic drug and the first high-affinity synaptic vesicle protein 2A(SV2A)ligand.It has rapid absorption,high bioavailability,and few drug interactions.Brivaracetam has been approved as monotherapy or adjuvant for partial-onset seizures with or without secondary generalization in patients 4 years and older with epilepsy.The antiepileptic mechanism,pharmacokinetics,clinical efficacy,safety and application during pregnancy were reviewed in this paper to provide more effective choices for treatment of epileptic.

关 键 词：布瓦西坦 抗癫痫药 药动学 药效学 

分 类 号：R971.6[医药卫生—药品]